Lomustine
1. Name of the medicinal product
Lomustine “medac” 40 mg
2. Qualitative and quantitative composition
Lomustine (CCNU) 40 mg per capsule
3. Pharmaceutical form
Hard capsule
4. Clinical particulars
4.1 Therapeutic indications
As palliative or supplementary treatment, usually in combination with radiotherapy and/or surgery as part of multiple drug regimens in:
– brain tumours (primary or metastatic)
– lung tumours (especially oat-cell carcinoma)
Hodgkin’s disease (resistant to conventional combination chemotherapy)
– malignant melanoma (metastatic)
Lomustine “medac” may also be of value as second-line treatment in Non-Hodgkin’s lymphoma, myelomatosis, gastrointestinal tumours, carcinoma of the kidney, the testis, the ovary, the cervix uteri and the breast.